SOUTH SAN FRANCISCO, Calif.,
Nov. 15, 2019 /PRNewswire/
-- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused
precision medicine company committed to the discovery and
development of targeted therapeutics to treat cancer, announced
that it will present data from an ongoing Phase 1/2 clinical trial
entitled "A Phase 1/2 Study in Patients with Solid Tumors Harboring
GNAQ/11 Mutations or PRKC Fusions" (ClinicalTrials.gov Identifier:
NCT03947385). This clinical trial is evaluating the
tolerability and preliminary clinical activity of IDE196 for the
treatment of MUM and other solid tumors harboring GNAQ or GNA11
(GNAQ/11) mutations activating the PKC signaling pathway.
An update on the Phase 1 Dose-Escalation portion of the ongoing
Phase 1/2 clinical trial will be provided, including:
- Dosing schema for dose escalation cohorts
- Patient enrollment by dose cohort
- Patient baseline characteristics
- Summary of adverse events
- Duration of treatment through data cut-off (October 28, 2019)
Data will be presented at the 16th International
Congress for the Society for Melanoma Research (SMR Congress) at
the Grand America Hotel in Salt Lake
City, Utah, November 20-23,
2019.
Dr. Matteo Carlino, Medical
Oncologist, Westmead Hospital and University of Australia, Westmead, Australia, will provide a poster presentation
at the SMR Congress on November 20,
2019, entitled: "A phase 1/2 study of IDE196 in patients
with metastatic uveal melanoma or solid tumors harboring GNAQ/11
mutations or PRKC fusions."
Dr. Meredith McKean, MD, MPH,
Investigator, Melanoma Research Program at Sarah Cannon Research
Institute, Nashville, TN, will
provide an oral presentation, at a related meeting hosted by the
Melanoma Research Foundation's CURE Ocular Melanoma (OM) initiative
in conjunction with the SMR Congress, on November 20, 2019.
___________________
About IDEAYA Biosciences
IDEAYA is an oncology-focused precision medicine company
committed to the discovery and development of targeted therapeutics
for patient populations selected using molecular diagnostics.
IDEAYA's approach integrates capabilities in identifying and
validating translational biomarkers with small molecule drug
discovery to select patient populations most likely to benefit from
the targeted therapies IDEAYA is developing. IDEAYA is
applying these capabilities across multiple classes of precision
medicine, including direct targeting of oncogenic pathways and
synthetic lethality – which represents an emerging class of
precision medicine targets.
__________________
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to (i) update on
Phase 1 Dose-Escalation portion of ongoing Phase 1/2 basket trial,
(ii) Phase 2 dose selection and expansion for the IDE196 Phase 2
clinical trial, and (iii) release of interim data for the IDE196
Phase 1/2 basket trial. Such forward-looking statements
involve substantial risks and uncertainties that could cause
IDEAYA's preclinical and clinical development programs, future
results, performance or achievements to differ significantly from
those expressed or implied by the forward-looking statements. Such
risks and uncertainties include, among others, the uncertainties
inherent in the drug development process, including IDEAYA's
programs' early stage of development, the process of designing and
conducting preclinical and clinical trials, the regulatory approval
processes, the timing of regulatory filings, the challenges
associated with manufacturing drug products, IDEAYA's ability to
successfully establish, protect and defend its intellectual
property and other matters that could affect the sufficiency of
existing cash to fund operations. IDEAYA undertakes no obligation
to update or revise any forward-looking statements. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to the business of IDEAYA in
general, see IDEAYA's recent Quarterly Report on Form 10-Q filed on
August 12, 2019 and any current and
periodic reports filed with the U.S. Securities and Exchange
Commission.
___________________
View original content to download
multimedia:http://www.prnewswire.com/news-releases/phase-12-clinical-trial-progress-for-ide196-to-be-presented-at-society-for-melanoma-research-congress-300959008.html
SOURCE IDEAYA Biosciences, Inc.